{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:48:59Z","timestamp":1770418139422,"version":"3.49.0"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Novartis Pharma Portugal"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the efficacy of biologic DMARDs (bDMARDs) in achieving Assessment of Spondyloarthritis International Society partial remission (ASAS-PR) and\/or Ankylosing Spondylitis Disease Activity Score inactive disease (ASDAS-ID), as remission-like surrogates, in axial SpA (axSpA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from randomized controlled trials (RCTs), including long-term extensions, were included. A systematic literature review was performed using the MEDLINE database (first search May 2018, updated February 2020) and PICO criteria according to Patients\u2014adults with radiographic or non-radiographic axSpA; Intervention\u2014any bDMARD; Comparator\u2014placebo and\/or any different drug; Outcomes\u2014ASAS-PR and\/or ASDAS-ID as primary or secondary endpoints. Meta-analysis was performed after assessment of the homogeneity of study designs, populations and outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After screening 155 references, a total of 22 RCTs and 28 long-term extensions were retrieved. ASAS-PR was the dominant remission-like definition used. Concerning TNF inhibitors, 14\/17 RCTs provided evidence of efficacy in reaching remission at different time points: 12, 16, 24 and 28\u2009weeks (ASAS-PR in 16\u201362% of patients and ASDAS-ID in 24\u201340% of patients). With a limited number of studies available, IL-17A inhibitors exhibited remission rates of 15\u201321% for ASAS-PR and 11\u201316% for ASDAS-ID at week 16. A meta-analysis regarding ASAS-PR was performed considering RCTs with a similar duration (12, 16 or 24\u2009weeks). The relative risk for achieving remission was 3.864 (95% CI 2.937, 5.085).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>bDMARDs have a clear impact in axSpA remission evaluated by ASAS-PR. Nevertheless, these data show an unmet need for improved reporting of remission-like outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa268","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T19:10:08Z","timestamp":1587669008000},"page":"3158-3171","source":"Crossref","is-referenced-by-count":19,"title":["Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis"],"prefix":"10.1093","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0600-876X","authenticated-orcid":false,"given":"Ana Rita","family":"Cruz-Machado","sequence":"first","affiliation":[{"name":"Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Lisbon Academic Medical Centre, Lisbon, Portugal"},{"name":"Rheumatology Research Unit, Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7217-0469","authenticated-orcid":false,"given":"Santiago","family":"Rodrigues-Manica","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal"},{"name":"CEDOC, NOVA Medical School, Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6808-6520","authenticated-orcid":false,"given":"Joana Leite","family":"Silva","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Unidade Local de Sa\u00fade do Alto Minho, Ponte de Lima, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3190-7479","authenticated-orcid":false,"given":"Irina","family":"Alho","sequence":"additional","affiliation":[{"name":"Genetics Laboratory, Institute of Environmental Health, Lisbon Medical School, University of Lisbon, Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5331-2257","authenticated-orcid":false,"given":"Constan\u00e7a","family":"Coelho","sequence":"additional","affiliation":[{"name":"Genetics Laboratory, Institute of Environmental Health, Lisbon Medical School, University of Lisbon, Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5736-9138","authenticated-orcid":false,"given":"Joana","family":"Duarte","sequence":"additional","affiliation":[{"name":"Medical Department, Novartis Pharma, Porto Salvo, Portugal"}]},{"given":"Cl\u00e1udia","family":"Flor\u00eancio","sequence":"additional","affiliation":[{"name":"Medical Department, Novartis Pharma, Porto Salvo, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2816-7705","authenticated-orcid":false,"given":"Fernando M","family":"Pimentel-Santos","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal"},{"name":"CEDOC, NOVA Medical School, Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6940-0905","authenticated-orcid":false,"given":"Jos\u00e9","family":"Tavares-Costa","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Unidade Local de Sa\u00fade do Alto Minho, Ponte de Lima, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7170-8802","authenticated-orcid":false,"given":"Elsa","family":"Vieira-Sousa","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Lisbon Academic Medical Centre, Lisbon, Portugal"},{"name":"Rheumatology Research Unit, Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal"}]}],"member":"286","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"2020102707114421300_keaa268-B1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jbspin.2012.06.003","article-title":"Ankylosing spondylitis, spondyloarthropathy, spondyloarthritis, or spondylarthritis: what's in a name?","volume":"79","author":"Claudepierre","year":"2012","journal-title":"Joint Bone Spine"},{"key":"2020102707114421300_keaa268-B2","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/ard.2009.108217","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B3","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B4","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/ard.2008.091793","article-title":"Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine","volume":"68","author":"Landewe","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","article-title":"TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort","volume":"77","author":"Molnar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B6","first-page":"997.2","article-title":"SAT0268 Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis","volume":"77","author":"Baraliakos","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B7","doi-asserted-by":"crossref","first-page":"e001005","DOI":"10.1136\/rmdopen-2019-001005","article-title":"Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study","volume":"5","author":"Baraliakos","year":"2019","journal-title":"RMD Open"},{"key":"2020102707114421300_keaa268-B8","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2217\/imt-2019-0094","article-title":"Ixekizumab for treating ankylosing spondylitis","volume":"11","author":"Kiwalkar","year":"2019","journal-title":"Immunotherapy"},{"key":"2020102707114421300_keaa268-B9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B10","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2020102707114421300_keaa268-B11","doi-asserted-by":"crossref","first-page":"i93","DOI":"10.1136\/annrheumdis-2011-200798","article-title":"How to define remission in ankylosing spondylitis?","volume":"71","author":"Sieper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B12","first-page":"S33","article-title":"Remission and possible discontinuation of biological therapy in axial spondyloarthritis","volume":"31","author":"Braun","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2020102707114421300_keaa268-B13","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.berh.2014.10.005","article-title":"Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis","volume":"28","author":"Poddubnyy","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2020102707114421300_keaa268-B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20090","article-title":"Tumour necrosis factor-\u03b1 inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation","volume":"20","author":"Corbett","year":"2016","journal-title":"Health Technol Assess"},{"key":"2020102707114421300_keaa268-B15","doi-asserted-by":"crossref","first-page":"e000396","DOI":"10.1136\/rmdopen-2016-000396","article-title":"Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"3","author":"Sepriano","year":"2017","journal-title":"RMD Open"},{"key":"2020102707114421300_keaa268-B16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B17","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states","volume":"77","author":"Machado","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B18"},{"key":"2020102707114421300_keaa268-B19","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/art.23606","article-title":"Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two","volume":"58","author":"Haibel","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2020102707114421300_keaa268-B20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","article-title":"Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial","volume":"73","author":"Huang","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B21","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study","volume":"73","author":"Landewe","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B23","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/rheumatology\/keu132","article-title":"Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial","volume":"53","author":"Bao","year":"2014","journal-title":"Rheumatology (Oxford"},{"key":"2020102707114421300_keaa268-B24","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2020102707114421300_keaa268-B25","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"2020102707114421300_keaa268-B26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2020102707114421300_keaa268-B27","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/art.24408","article-title":"Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis","volume":"60","author":"Barkham","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2020102707114421300_keaa268-B28","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/annrheumdis-2013-204963","article-title":"Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)","volume":"74","author":"Sieper","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13075-016-0930-4","article-title":"Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study","volume":"18","author":"Park","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2020102707114421300_keaa268-B30","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2020102707114421300_keaa268-B31","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2020102707114421300_keaa268-B32","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/ard.2006.056747","article-title":"Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis","volume":"65","author":"van der Heijde","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B33","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1136\/ard.2010.139261","article-title":"Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE)","volume":"70","author":"Dougados","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B34","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","article-title":"Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial","volume":"63","author":"Braun","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2020102707114421300_keaa268-B35","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2020102707114421300_keaa268-B36","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2020102707114421300_keaa268-B37","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"2020102707114421300_keaa268-B38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","article-title":"Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, part 1","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B39","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2020102707114421300_keaa268-B40","first-page":"238","article-title":"Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis","volume":"28","author":"Martin-Mola","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2020102707114421300_keaa268-B41","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.3899\/jrheum.140056","article-title":"Consistently good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial","volume":"41","author":"Song","year":"2014","journal-title":"J Rheumatol"},{"key":"2020102707114421300_keaa268-B42","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/annrheumdis-2015-207596","article-title":"Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study","volume":"75","author":"Maksymowych","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B43","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/acr.23276","article-title":"Effects of long-term etanercept treatment on clinical outcomes and objective signs of inflammation in early nonradiographic axial spondyloarthritis: 104-week results from a randomized, placebo-controlled study","volume":"69","author":"Dougados","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2020102707114421300_keaa268-B44","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/ard.2007.087270","article-title":"Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B45","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2011-200358","article-title":"Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis","volume":"71","author":"Sieper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B46","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/annrheumdis-2014-205862","article-title":"Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study","volume":"74","author":"Deodhar","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B47","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/art.38973","article-title":"Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2020102707114421300_keaa268-B48","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study","volume":"76","author":"Braun","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B49","first-page":"50","article-title":"Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the phase 3 MEASURE 1 trial","volume":"36","author":"Baraliakos","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2020102707114421300_keaa268-B50","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/acr.23233","article-title":"Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III study","volume":"69","author":"Marzo-Ortega","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2020102707114421300_keaa268-B51","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1002\/art.11104","article-title":"Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial","volume":"48","author":"Braun","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2020102707114421300_keaa268-B52","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/ard.2004.025130","article-title":"Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis","volume":"64","author":"Braun","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B53","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/rheumatology\/keh584","article-title":"Persistent clinical response to the anti-TNF-\u03b1 antibody infliximab in patients with ankylosing spondylitis over 3 years","volume":"44","author":"Braun","year":"2005","journal-title":"Rheumatology (Oxford"},{"key":"2020102707114421300_keaa268-B54","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/annrheumdis-2015-208783","article-title":"Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study","volume":"76","author":"Park","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B55","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/ard.2007.078139","article-title":"Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis","volume":"67","author":"Davis","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B56","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3899\/jrheum.081033","article-title":"Etanercept in the longterm treatment of patients with ankylosing spondylitis","volume":"36","author":"Dijkmans","year":"2009","journal-title":"J Rheumatol"},{"key":"2020102707114421300_keaa268-B57","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/acr2.11102","article-title":"Secukinumab 150\/300 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 3-year results from the phase 3 MEASURE 3 study","volume":"2","author":"Pavelka","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2020102707114421300_keaa268-B58","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B59","doi-asserted-by":"crossref","first-page":"e000592","DOI":"10.1136\/rmdopen-2017-000592","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2","volume":"3","author":"Marzo-Ortega","year":"2017","journal-title":"RMD Open"},{"key":"2020102707114421300_keaa268-B60","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"2020102707114421300_keaa268-B61","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2020102707114421300_keaa268-B62","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2020102707114421300_keaa268-B63","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","article-title":"Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results\u00a0from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2020102707114421300_keaa268-B64","author":"Higgins"},{"key":"2020102707114421300_keaa268-B65","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/11\/3158\/34038175\/keaa268.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/11\/3158\/34038175\/keaa268.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T12:06:56Z","timestamp":1603800416000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/11\/3158\/5874631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":65,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,7,22]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa268","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11]]},"published":{"date-parts":[[2020,7,22]]}}}